PAHC vs. IRON, EOLS, YMAB, ANAB, ARCT, SLN, NUVB, BCYC, PLRX, and SVRA
Should you be buying Phibro Animal Health stock or one of its competitors? The main competitors of Phibro Animal Health include Disc Medicine (IRON), Evolus (EOLS), Y-mAbs Therapeutics (YMAB), AnaptysBio (ANAB), Arcturus Therapeutics (ARCT), Silence Therapeutics (SLN), Nuvation Bio (NUVB), Bicycle Therapeutics (BCYC), Pliant Therapeutics (PLRX), and Savara (SVRA). These companies are all part of the "pharmaceutical preparations" industry.
Phibro Animal Health (NASDAQ:PAHC) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, community ranking, dividends, profitability, earnings, valuation and media sentiment.
Phibro Animal Health has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500.
In the previous week, Phibro Animal Health had 7 more articles in the media than Disc Medicine. MarketBeat recorded 9 mentions for Phibro Animal Health and 2 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.71 beat Phibro Animal Health's score of 0.40 indicating that Disc Medicine is being referred to more favorably in the news media.
Phibro Animal Health has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Phibro Animal Health has a net margin of 1.51% compared to Disc Medicine's net margin of 0.00%. Phibro Animal Health's return on equity of 16.67% beat Disc Medicine's return on equity.
Phibro Animal Health currently has a consensus target price of $15.33, indicating a potential downside of 10.17%. Disc Medicine has a consensus target price of $57.29, indicating a potential upside of 92.30%. Given Disc Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Disc Medicine is more favorable than Phibro Animal Health.
99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 4.7% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Phibro Animal Health received 282 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 71.88% of users gave Disc Medicine an outperform vote while only 60.04% of users gave Phibro Animal Health an outperform vote.
Summary
Phibro Animal Health beats Disc Medicine on 12 of the 17 factors compared between the two stocks.
Get Phibro Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAHC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phibro Animal Health Competitors List
Related Companies and Tools
